Active Deal Flow Omega Funds demonstrates strong life sciences deal flow with recent clinical-stage investments in Windward Bio and Caldera Therapeutics, signaling continued appetite for oncology, immunology, rare diseases, and precision medicine opportunities. Use this to source high-potential deals and offer co-investment options.

Co-investment Network The firm co-invests with top-tier partners such as OrbiMed, Novo Holdings, SR One and others, indicating openness to syndication and a broad biotech investor network. Position as a gateway for exclusive co-investments and strategic partnerships.

Value Add Partnerships Omega employs multiple instruments from venture to late-stage and secondary, suggesting appetite for portfolio-support services. Propose CRO, regulatory, manufacturing, and data analytics partnerships that enhance portfolio value.

Leadership and Talent Leadership movements, including Francesco Draetta’s promotion and the addition of an executive partner, signal emphasis on strong governance. Offer executive search, interim leadership, and talent advisory services for portfolio companies.

Global Expansion Enablement With US headquarters and international activity, Omega seeks cross-border financing and global reach. Provide regulatory navigation, international clinical operations, manufacturing scale-up, and market-access support for portfolio expansion.